"Fruit Fly Model Provides Personalized Cancer Therapy Recommendation"
A group led by researchers at the Icahn School of Medicine at Mount Sinai has built a fruit fly model to develop a personalized therapy for a patient with treatment-resistant metastatic KRAS-mutation colorectal cancer (CRC). “Identifying an effective, unique drug combination emphasized the potential for moderately high-throughput screen that can be accomplished in a timeframe that is useful for treating the patient,” the study authors noted. The team believes that future studies will potentially improve the technology’s ability to generate more defined models to capture the genomic complexity of tumor genomic landscapes. By focusing on each cancer’s genomic complexity, the team believes the personalized approach could provide alternative treatment options for diseases such as KRAS-mutant CRC.
— Ross L. Cagan, PhD, Director, The Center for Personalized Cancer Therapeutics, Professor, Cell, Developmental & Regenerative Biology, Oncological Sciences, Ophthalmology, Icahn School of Medicine at Mount Sinai
Additional coverage: New Scientist; The Scientist